QIAGEN announces custom digital PCR assays for Bundibugyo ebolavirus research
Key Highlights
- Assays are designed for research use only and are compatible with the QIAcuity digital PCR system.
- Target the nucleoprotein (NP) and VP35 regions of Bundibugyo ebolavirus, with no mismatches against current outbreak sequences.
QIAGEN announced the availability of two custom-designed research-use-only (RUO) digital PCR assays to support infectious disease research and surveillance efforts related to the Bundibugyo ebolavirus outbreak.
The assays are designed for use with the QIAcuity digital PCR system and are intended to help qualified laboratories evaluate emerging pathogen targets in research, wastewater surveillance and other environmental monitoring settings. They were developed using publicly available genomic sequence information released during the outbreak response and are part of QIAGEN’s broader Sample to Insight portfolio supporting infectious disease research workflows.
The assays target the nucleoprotein (NP) and VP35 regions of the virus. Initial in silico sequence analysis showed no mismatches against the currently published outbreak sequences reviewed by QIAGEN.
The assays are intended for research use only and are not intended for diagnostic procedures.
QIAGEN’s current portfolio supporting this infectious disease outbreak includes:
- Research-use-only digital PCR assays targeting the NP and VP35 regions of Bundibugyo ebolavirus are available through QIAGEN’s custom assay workflow on a make-to-order basis.
- QIAseq sequencing panels are available from stock for fast delivery.
- Existing sample preparation and molecular workflow kits are available from stock to support nucleic acid processing for downstream digital PCR and next-generation sequencing workflows to support wastewater surveillance and molecular research applications.
The QIAcuity digital PCR system supports sensitive nucleic acid detection and quantification across a range of research applications, including infectious disease research and environmental surveillance. Combined with QIAGEN’s broader Sample to Insight portfolio, the platform enables laboratories to rapidly adapt existing workflows as new pathogen targets emerge.
